Recent Updates
Recently added Catalysts
LTRN Positive Sentiment

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

Thursday, September 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantern Pharma Inc. will host a live webinar on September 23, 2026, to discuss its Open-Medicine AI platform. The presentation will cover the business model, development roadmap, and value proposition of this multi-agentic AI system designed for therapeutic development. This initiative highlights the company's focus on precision oncology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lantern Pharma is leveraging AI for precision oncology therapies.
  • The upcoming webinar will provide insights into their innovative platform.
  • Open-Medicine AI aims to enhance therapeutic development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
4%
average across 5 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxel
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeuti

Frequently Asked Questions

What is the Open-Medicine AI platform?

Open-Medicine AI is a multi-agentic platform developed by Lantern Pharma for therapeutic development.

When is the Lantern Pharma webinar scheduled?

The webinar is scheduled for September 23, 2026, at 12:30 PM Eastern.

What topics will be covered in the webinar?

The webinar will discuss the business model, development roadmap, and value proposition of Open-Medicine AI.

Who is presenting the webinar?

The webinar will be hosted by Lantern Pharma Inc., a clinical-stage biopharma company.

ShareAdd on Google
Tags: LTRN Viatris Investor Conferences Healthcare Lantern Pharma AI platform precision oncology therapeutic development webinar
Last updated: Sep 17, 2026

Biotech snapshot

Cash runway
$7M liquidity · $1M/mo burn
~7 mo
Medium dilution risk
Lead asset
Tavocept in combination with cisplatin and either docetaxel or paclitaxelPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+20%
best trade around LTRN's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for LTRN.

See every catalyst's timing & PoA →